면역측정 시장 : 유형, 기술, 기기, 검체 유형, 감지 방식, 응용 분야, 최종 사용자, 도입 형태별 - 세계 시장 예측(2026-2032년)

The Immunoassay Market is projected to grow by USD 49.98 billion at a CAGR of 7.36% by 2032.

Immunoassay is a core analytical technology in modern diagnostics, using highly specific antigen-antibody binding to detect biomarkers in blood, serum, plasma, saliva, urine, and other specimen types. Established formats such as enzyme-linked immunosorbent assay (ELISA), chemiluminescent immunoassay, fluorescence immunoassay, radioimmunoassay, and lateral flow immunoassay support clinical testing across infectious disease, oncology, cardiology, endocrinology, allergy, toxicology, autoimmune disease, fertility, and therapeutic drug monitoring.

Demand is supported by measurable healthcare needs, including aging populations, chronic disease prevalence, antimicrobial resistance surveillance, prenatal screening, blood safety, and pandemic preparedness. The World Health Organization reports that noncommunicable diseases account for about 74% of global deaths, reinforcing the need for scalable biomarker testing. Immunoassay remains strategically important because it combines scalable throughput, clinical familiarity, automation compatibility, cost-efficient workflows, and rapid turnaround for centralized laboratories and decentralized point-of-care testing.

Transformative Shifts in the Immunoassay Landscape

The immunoassay landscape is shifting from standalone, manual workflows toward automated, connected, and multiplexed diagnostic ecosystems. Clinical laboratories are prioritizing high-throughput analyzers, standardized reagent platforms, quality controls, and interfaces with laboratory information systems to reduce variability, improve traceability, and support faster clinical decisions.

At the same time, point-of-care immunoassay adoption is expanding as health systems seek earlier detection outside central labs, especially in emergency departments, primary care, pharmacies, rural clinics, and outbreak settings. Regulatory scrutiny is also increasing, particularly under the EU In Vitro Diagnostic Regulation and FDA oversight of higher-risk diagnostics, making analytical validation, clinical performance evidence, risk management, usability, and post-market surveillance essential competitive differentiators.

Cumulative Impact of Artificial Intelligence on Immunoassay

Artificial intelligence is becoming an operational accelerator for immunoassay development and deployment. AI-enabled image analysis can improve interpretation of lateral flow and fluorescence results, while machine learning supports assay optimization by modeling antibody-antigen interactions, background noise, cross-reactivity risk, interference patterns, and calibration curve performance.

In laboratories, AI contributes to predictive maintenance, workload forecasting, reflex-testing rules, result verification, and anomaly detection in quality control data. Its strongest near-term value is not replacing immunoassay science but improving reproducibility, throughput, and clinical integration when paired with validated datasets, transparent governance, cybersecurity controls, human oversight, and regulatory-grade documentation.

Key Regional Insights for Immunoassay

Asia-Pacific is a dynamic immunoassay region because China, India, Japan, South Korea, Australia, and Southeast Asian economies combine large patient pools with expanding diagnostic infrastructure, rising chronic disease testing, and greater use of automated and point-of-care platforms. North America remains highly mature, supported by regulated innovation, hospital networks, reference laboratories, reimbursement pathways, public health testing capacity, and strong uptake of automated immunoassay platforms for infectious disease, endocrine, cardiac, oncology, and therapeutic monitoring applications.

Europe is shaped by advanced laboratory medicine, national screening programs, accreditation practices, and stricter In Vitro Diagnostic Regulation evidence requirements, which increase the importance of clinical validation and post-market performance monitoring. Latin America is improving immunoassay access through private laboratory chains, public screening initiatives, and infectious disease testing for conditions such as dengue, HIV, hepatitis, and respiratory infections. The Middle East is investing in hospital modernization, preventive screening, specialty diagnostics, and laboratory automation, while Africa's opportunity is strongly linked to scalable point-of-care immunoassays for HIV, malaria, hepatitis, pregnancy, tuberculosis screening support, and outbreak response, where decentralized testing can close access gaps in underserved areas.

Key Group Insights for Immunoassay

ASEAN countries are expanding immunoassay use through infectious disease surveillance, maternal health programs, hospital laboratory upgrades, and rising private diagnostics demand across urban centers. The GCC is investing in high-acuity hospitals, laboratory automation, local health security capacity, and preventive screening aligned with national health transformation agendas. The European Union is increasingly evidence-driven under IVDR, favoring suppliers with robust clinical validation, traceability, quality management systems, and documented post-market surveillance.

BRICS markets offer scale and localization potential, particularly where public procurement, domestic manufacturing policies, technology transfer, and access-oriented pricing influence adoption. G7 markets lead in premium analyzer adoption, companion diagnostics, reimbursement standards, laboratory accreditation, and digital laboratory integration. NATO members' broader emphasis on health security also supports immunoassay capacity for biodefense readiness, blood safety, outbreak preparedness, military medical services, and deployable diagnostics in emergency settings.

Key Country Insights for Immunoassay

The United States leads immunoassay commercialization through large reference laboratories, integrated hospital systems, established FDA pathways, and strong demand for oncology, cardiac, infectious disease, autoimmune, allergy, and endocrine testing. Canada emphasizes quality-assured diagnostics within publicly funded care, while Mexico and Brazil combine infectious disease testing needs, chronic disease screening, and expanding private laboratory networks. The United Kingdom, Germany, France, Italy, and Spain remain central to European immunoassay adoption, supported by established clinical guidelines, laboratory accreditation, universal or near-universal healthcare systems, and advanced infrastructure.

Russia maintains demand for essential diagnostics despite procurement complexity and supply chain constraints. China and India are major growth engines due to population scale, chronic disease burden, domestic manufacturing capacity, expanding hospital networks, and public health testing needs. Japan, Australia, and South Korea are advanced immunoassay markets where automation, high-quality reagents, aging demographics, precision diagnostics, and strong laboratory quality standards continue to drive adoption across centralized and decentralized testing environments.

Actionable Recommendations for Immunoassay Industry Leaders

Industry leaders should prioritize assay menus with clear clinical utility, including infectious disease, cardiac markers, thyroid function, fertility, oncology biomarkers, autoimmune testing, allergy diagnostics, inflammation markers, and therapeutic drug monitoring. Competitive advantage will come from proven sensitivity, specificity, reproducibility, lot-to-lot consistency, calibration stability, interference management, and seamless analyzer integration.

Organizations should also invest in regional regulatory readiness, IVDR transition planning, quality system maturity, cybersecurity for connected analyzers, and AI governance. Partnerships with hospitals, reference laboratories, public health agencies, academic centers, and local distributors can improve evidence generation, reimbursement access, user training, service uptime, and adoption in both mature and emerging immunoassay markets.

Research Methodology

This executive summary is based on a structured review of publicly available, authoritative sources, including regulatory agency guidance, clinical laboratory standards, World Health Organization resources, peer-reviewed literature, health system reports, public procurement information, and disclosures from established diagnostics manufacturers.

The analysis evaluates immunoassay technologies, clinical applications, regional healthcare drivers, country-level diagnostic infrastructure, regulatory conditions, laboratory automation trends, point-of-care testing adoption, and AI-enabled workflow integration. Insights were synthesized using evidence triangulation, prioritizing verifiable facts over unsupported claims and excluding speculative data that could not be linked to credible healthcare, diagnostics, regulatory, or laboratory medicine indicators.

Conclusion

Immunoassay will remain a foundational diagnostics category because it addresses high-volume clinical needs while adapting to automation, multiplexing, point-of-care testing, digital connectivity, and AI-enabled workflow support. The category's long-term relevance is reinforced by chronic disease management, infectious disease surveillance, preventive screening, blood safety, therapeutic monitoring, and precision medicine.

The next phase of leadership will depend on validated performance, regulatory discipline, accessible pricing, resilient supply chains, and intelligent workflow integration. Organizations that combine scientific reliability with scalable manufacturing, strong quality systems, clinical evidence, and evidence-based commercialization will be best positioned to meet demand across global immunoassay markets.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Immunoassay Market, by Type

• 7.1. Qualitative Immunoassays
• 7.2. Quantitative Immunoassays

8. Immunoassay Market, by Technology

• 8.1. Enzyme Immunoassays
• 8.2. Enzyme-Linked Immunosorbent Assay
• 8.3. Fluorescent Immunoassay
• 8.4. Lateral Flow Assay
• 8.5. Radioimmunoassay
• 8.6. Western Blot

9. Immunoassay Market, by Instruments

• 9.1. Analyzers & Kits
• 9.2. Biosensors
• 9.3. Microfluidic Devices
• 9.4. Microplates
• 9.5. PCR Devices
• 9.6. Reagents
  • 9.6.1. Antibodies
  • 9.6.2. Antigens
  • 9.6.3. Blocking Reagents
  • 9.6.4. Buffers & Standards
  • 9.6.5. Enzymes
  • 9.6.6. Substrates
• 9.7. Software & Services

10. Immunoassay Market, by Sample Types

• 10.1. Blood Samples
• 10.2. Saliva Samples
• 10.3. Tissue Samples
• 10.4. Urine Samples

11. Immunoassay Market, by Detection Modes

• 11.1. Chemiluminescent
• 11.2. Colorimetric
• 11.3. Fluorometric
• 11.4. Radioisotopic

12. Immunoassay Market, by Application Areas

• 12.1. Allergy
• 12.2. Autoimmune Diseases
• 12.3. Cardiology
• 12.4. Endocrinology
• 12.5. Infectious Diseases
• 12.6. Oncology
• 12.7. Toxicology
  • 12.7.1. Drug Screening
  • 12.7.2. Environmental Testing

13. Immunoassay Market, by End Users

• 13.1. Contract Research Organizations
• 13.2. Diagnostic Laboratories
• 13.3. Hospitals & Clinics
• 13.4. Pharmaceutical & Biotechnology Companies
• 13.5. Research Institutions

14. Immunoassay Market, by Deployment Types

• 14.1. Laboratory Tests
• 14.2. Point-of-care Test

15. Immunoassay Market, by Region

• 15.1. Asia-Pacific
• 15.2. North America
• 15.3. Latin America
• 15.4. Europe
• 15.5. Middle East
• 15.6. Africa

16. Immunoassay Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Immunoassay Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. Abbott Laboratories
• 19.2. Agilent Technologies Inc.
• 19.3. ANP Technologies, Inc.
• 19.4. Autobio Diagnostics Co., Ltd.
• 19.5. Becton, Dickinson and Company
• 19.6. Bio-Rad Laboratories, Inc.
• 19.7. Bio-Techne Corporation
• 19.8. bioMerieux S.A.
• 19.9. Biosurfit SA
• 19.10. Boditech Med Inc.
• 19.11. Danaher Corporation
• 19.12. Diasorin S.p.A.
• 19.13. Dynex Technologies, Inc.
• 19.14. Epitope Diagnostics Inc.
• 19.15. F. Hoffmann-La Roche Ltd.
• 19.16. Fapon Biotech Inc.
• 19.17. H.U. Group Holdings Inc.
• 19.18. J. Mitra & Co. Pvt. Ltd.
• 19.19. Kamiya Biomedical Company
• 19.20. Merck KGaA
• 19.21. MiCo BioMed, Inc.
• 19.22. NanoEntek
• 19.23. Nanomix, Inc.
• 19.24. OPKO Health, Inc.
• 19.25. Promega Corporation
• 19.26. QIAGEN N.V.
• 19.27. Quanterix Corporation
• 19.28. Randox Laboratories Ltd.
• 19.29. Shenzhen Micropoint Biotechnologies Co., Ltd.
• 19.30. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 19.31. Siemens Healthineers AG
• 19.32. Sysmex Corporation
• 19.33. Thermo Fisher Scientific Inc.
• 19.34. Tosoh Corporation
• 19.35. WAK-Chemie Medical GmbH
• 19.36. Zoetis Inc.
• 19.37. Zybio Inc.